P377: Serum adalimumab trough levels required for mucosal healing during maintenance therapy in patients with Crohn’s diseaseECCO '16 Amsterdam
2016
P378: The outcomes of a clinical care pathway for inflammatory bowel disease surgeryECCO '16 Amsterdam
2016
P379: Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulationECCO '16 Amsterdam
2016
P380: Comparative study of infliximab and adalimumab induction therapy for clinical remission and mucosal healing in paediatric patients with active Crohn’s diseaseECCO '16 Amsterdam
2016
P381: An observational study of adverse events of patients with inflammatory bowel disease receiving parenteral ironECCO '16 Amsterdam
2016
P382: Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel diseaseECCO '16 Amsterdam
2016
P383: Short- and long-term outcomes of infliximab and calcineurin inhibitor treatment for steroid-refractory ulcerative colitisECCO '16 Amsterdam
2016
P384: The usefulness of salazosulfapyridine for
patients with ulcerative colitis refractory to mesalazineECCO '16 Amsterdam
2016
P385: Predictors of tissue healing in ulcerative colitis patients treated with anti-TNFECCO '16 Amsterdam
2016
P386: Anti-TNF alpha as induction and maintenance therapy in ulcerative colitis patients in the BioColitis Registry in GermanyECCO '16 Amsterdam
2016
P387: Does standard therapy in paediatric Crohn’s disease really prevent our patients from the need of early initiation of anti-TNF treatment?ECCO '16 Amsterdam
2016
P388: Clinical care pathways are needed to decrease variability in the management of the hospitalised ulcerative colitis patientECCO '16 Amsterdam
2016
P389: The value of oxidative stress parameters to predict histological severity in ulcerative colitisECCO '16 Amsterdam
2016
P390: To double dose or not to double dose? That is the question: Single centre experience in the use of infliximab antibodies and levels in a paediatric IBD (pIBD) cohortECCO '16 Amsterdam
2016
P391: Gender differences in adalimumab continuation rates: Results of a Crohn’s disease cohortECCO '16 Amsterdam
2016
P393: Investigation of Crohn’s disease patients receiving anti-TNF α therapy after surgery for intestinal stenosisECCO '16 Amsterdam
2016
P394: Psychosexual dysfunction in a cohort of Greek inflammatory bowel disease patients in clinical remission: preliminary resultsECCO '16 Amsterdam
2016